The novel cyclooxygenase-2 inhibitor GW637185X protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity

NeuroReport

Volumn 19, Issue 6, 2008, Pages 657-660

  Aguirre, Jose A ^a   Leo, Giuseppina ^b   Cueto, Raquel ^a   Andbjer, Beth ^c   Naylor, Alan ^d   Medhurst, Andrew D ^d   Agnati, Luigi F ^b   Fuxe, Kjell ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Basal ganglia; Cyclooxygenase 2 inhibitor GW637185X; Microdensitometry; Mouse; Neuroprotection; Parkinson's disease; Stereology tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOOXYGENASE 2 INHIBITOR; GW 637185X; N (2 METHYLPROPYL) 4 [4 (METHYLSULFONYL)PHENYL] 6 (TRIFLUOROMETHYL) 2 PYRIMIDINAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; IMMUNOREACTIVITY; MALE; MICRODENSITOMETRY; MOUSE; NERVE ENDING; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; STEREOLOGY;

ANIMALS; BRAIN; CYCLOOXYGENASE 2 INHIBITORS; DOPAMINE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; TYROSINE 3-MONOOXYGENASE;

EID: 41749093649     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3282fb7898     Document Type: Article

References (25)

1. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-1291.
2. McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Mov Disord 1997; 12:855-858.
3. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991:214-228.
4. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003; 100:5473-5478.
5. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001; 39:167-174.
6. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, et al. COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 2003; 991:272-277.
7. Reksidler AB, LimaMM, Zanata SM, Machado HB, da Cunha C, Andreatini R, et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007; 560:163-175.
8. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 2002; 329:354-358.
9. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 2003; 14:1927-1929.
10. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 1995; 64:1645-1654.
11. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101:665-670.
12. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003; 18:121-129.
13. Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, et al. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 2004; 15:610-617.
14. Kyrkanides S, Moore AH, Olschowka JA, Daeschner JC, Williams JP, Hansen JT, et al. Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. Brain Res Mol Brain Res 2002; 104:159-169.
15. Molina-Holgado E, Arevalo-Martin A, Vela JM, Guaza C. Theiler's virus encephalomyelitis infection as a model for multiple sclerosis: cytokines and pathogenic mechanisms. Rev Neurol 2002; 35:973-978.
16. Araki E, Forster C, Dubinsky JM, Ross ME, Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 2001; 32:2370-2375.
17. Brambilla R, Abbracchio MP. Modulation of cyclooxygenase-2 and brain reactive astrogliosis by purinergic P2 receptors. Ann N Y Acad Sci 2001; 939:54-62.
18. Wang CZ, Johnson KM. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 2005; 81:284-292.
19. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18:315-321.
20. Green RH, Hartley CD, Naylor A, Payne JJ, Pegg NA. Pyrimidine derivatives. W.O. Pat. Application No. 01/38311 A2, pp. 1-28, 2001.
21. Aguirre JA, Cueto R, Leo G, Andbjer B, Medhurst AD, Agnati LF, Fuxe K. A novel inhibitor of cyclooxygenase 2 fully protects nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals against acute MPTP toxicity in mice. 7th IBRO World Congress of Neuroscience. Melbourne, Australia; 2007. p. 337.
22. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 2005; 1033:216-220.
23. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997.
24. Agnati LF, Fuxe K, Benfenati F, Zini I, Zoli M, Fabbri L, et al. Computer-assisted morphometry and microdensitometry of transmitter-identified neurons with special reference to the mesostriatal dopamine pathway. Methodological aspects. Acta Physiol Scand Suppl 1984; 532:5-36.
25. Zoli M, Ferraguti F, Ingletti M, Zini I, Fuxe K, Agnati LF. Regional increases in ornithine decarboxylase mRNA levels in the rat brain after partial mesodiencephalic hemitransection as revealed by in situ hybridization histochemistry. Neurochem Int 1991; 18:347-352.